MRK.N
Latest Trade
79.62USDChange
2.61(+3.39%)Volume
1,245,823Today's Range
-
79.8052 Week Range
-
91.40As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 77.01 |
|---|---|
Open | 77.26 |
Volume | 1,245,823 |
3M AVG Volume | 288.03 |
Today's High | 79.80 |
Today's Low | 77.26 |
52 Week High | 91.40 |
52 Week Low | 70.90 |
Shares Out (MIL) | 2,525.94 |
Market Cap (MIL) | 194,522.90 |
Forward P/E | 13.34 |
Dividend (Yield %) | 3.58 |
Merck And Ridgeback's Molnupiravir, Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval For Emergency In Japan
Merck And Ridgeback’S Molnupiravir Receives U.S. FDA Emergency Use Authorization For The Treatment Of High-Risk Adults With Mild To Moderate Covid-19
FDA Says Molnupiravir Is Not Recommended For Use During Pregnancy
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.
Industry
Biotechnology & Drugs
Contact Info
2000 Galloping Hill Rd
KENILWORTH, NJ
07033-1310
United States
+1.908.7404000
http://www.merck.com/Executive Leadership
Kenneth C. Frazier
Executive Chairman of the Board
Robert M. Davis
President, Chief Executive Officer, Director
Caroline Litchfield
Chief Financial Officer, Executive Vice President
Franklin K. Clyburn
President, Human Health, Head of Human Health Commercial and Marketing
Dean Y. Li
President - Merck Research Laboratories
Price To Earnings (TTM) | 30.42 |
|---|---|
Price To Sales (TTM) | 4.08 |
Price To Book (MRQ) | 5.43 |
Price To Cash Flow (TTM) | 20.00 |
Total Debt To Equity (MRQ) | 73.87 |
LT Debt To Equity (MRQ) | 64.00 |
Return on Investment (TTM) | 9.27 |
Return on Equity (TTM) | 7.03 |
Britain and Israel are overhauling their COVID-19 testing policies as governments seek to ease the burden on laboratories and struggle with tight supplies of kits amid soaring infection rates fuelled by the Omicron variant.
India has not added Merck's COVID-19 pill to its national treatment protocol for the disease due to known safety concerns that have restricted its use elsewhere, a senior health official told a media briefing on Wednesday.
South Korea signed an agreement to buy additional courses of Pfizer Inc's antiviral COVID-19 pill Paxlovid to cover 400,000 people, the Korea Disease Control and Prevention Agency (KDCA) said on Wednesday.
India has not added Merck's COVID-19 pill in its national treatment protocol for the disease due to some "major safety concerns", a senior health official told a media briefing on Wednesday.
Indian drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday.
Indian drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir, and price it at 35 rupees ($0.4693) per capsule, a company spokesperson said on Tuesday.
Belgium has agreed to buy 10,000 courses each of the COVID-19 antiviral oral treatments developed by Pfizer and Merck & CO, a spokesman for the health ministry told Reuters in an emailed statement on Monday.
Belgium will buy 10,000 courses each of the COVID-19 antiviral oral treatments developed by Pfizer and Merck & CO, a spokesman for the health ministry said in an emailed statement.
Prime Minister Naftali Bennett said on Sunday that Israel would offer a fourth dose of COVID-19 vaccine to people over 60 and to medical staff as it faces a surge in Omicron variant infections.
India has approved Merck's COVID-19 pill and two more vaccines for emergency use as the world's second most populous country braces for a possible spike in coronavirus cases due to the rapidly spreading Omicron variant.
India's drug regulator expert committee recommended emergency use authorisation (EUA) for Merck & Co Inc's COVID-19 pill molnupiravir, and Serum Institute of India's covovax and Biological E's corbevax vaccines, the Economic Times reported on Tuesday.
* MERCK AND RIDGEBACK’S MOLNUPIRAVIR, AN INVESTIGATIONAL ORAL ANTIVIRAL COVID-19 TREATMENT, RECEIVES SPECIAL APPROVAL FOR EMERGENCY IN JAPAN
A Japanese health ministry panel on Friday recommended approval of the COVID-19 antiviral pill developed by Merck & Co Inc, part of Prime Minister Fumio Kishida's plan to roll out new treatments by year-end as concerns rise about the Omicron variant.
Japanese regulators on Friday approved the COVID-19 antiviral pill developed by Merck & Co Inc , national broadcaster NHK reported.
The U.S. on Thursday authorized Merck & Co's antiviral pill for COVID-19 for certain high-risk adult patients, a day after giving a broader go-ahead to a similar but more effective treatment https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-covid-19...
* Indexes up: Dow 0.62%, S&P 0.73%, Nasdaq 0.99% (Updates with mid-afternoon trading)
Available data indicates that both Merck's and Pfizer's COVID-19 anti-viral treatments are effective against the Omicron variant of the coronavirus, a top U.S. Federal Drug Administration official said on Thursday.
The U.S. Food and Drug Administration on Thursday authorized Merck & Co's antiviral pill for COVID-19, after giving the go-ahead to a similar treatment from Pfizer Inc. a day earlier.
The Philippines on Thursday approved emergency use of Merck & Co Inc's COVID-19 treatment pill for adult patients at risk of developing severe illness as it tries to boosts the country's arsenal of drugs to fight new variants.
France has cancelled its order for Merck & Co's COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.